Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Chang Chun, China Clinical Trials

A listing of Chang Chun, China clinical trials actively recruiting patients volunteers.

RESULTS

Found (25) clinical trials

A Study of PEG-somatropin in the Treatment of Children With Idiopathic Short Stature

This study aims to explore the optimal dose of pegylated recombinant human growth hormone (PEG-rhGH) injection to treat children with idiopathic short stature (ISS), evaluate its safety and efficacy, and provide scientific and reliable evidence for the medication dosage in Phase III clinical study.

Phase

0.0 miles

Learn More »

High Resolution Microendoscopy for the Detection of Esophageal Squamous Cell Neoplasia

Our central hypothesis is that HRME can improve the efficiency and clinical impact of endoscopic screening and surveillance of esophageal squamous cell neoplasia by providing in-vivo optical biopsies comparable to standard histology. Specifically, HRME will allow more detailed evaluation of Lugol's abnormal areas, allowing selective biopsy or removal of neoplastic …

Phase

0.0 miles

Learn More »

A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer

This is a Phase II, randomized, multicenter, 2-arm, open-label clinical trial designed to compare the safety and efficacy of RC48-ADC with that of capecitabine + lapatinib in participants with human epidermal growth factor receptor 2 (HER2)-positive locally advanced or metastatic breast cancer. Participants will be treated until disease progression (PD), …

Phase

0.0 miles

Learn More »

Dual TORC1/TORC2 Inhibitor ATG-008 (CC-223) in HBV Positive Advanced Hepatocellular Carcinoma (HCC) Subjects

This is an Asian multi-regional clinical trial (MRCT) in which ATG-008 will be administered orally to hepatitis B positive (HBV+) HCC subjects who have received at least one prior line of systemic therapy. It is designed as an open-label phase 2 trial evaluating the pharmacokinetics (PK), safety, tolerability and efficacy …

Phase

0.0 miles

Learn More »

Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat SGA Children With Short Stature

This was a multicenter, randomized phase II study, half of participants will receive the high dose, while the other half will receive the low dose.

Phase

0.0 miles

Learn More »

A Study of RC48 in Subjects With HER2 Overexpressed Metastatic Biliary Tract Cancer.

This study will evaluate the efficacy and safety of intravenous RC48-ADC in patients with locally advanced or metastatic HER2 overexpressed biliary tract cancer who have failed first-line chemotherapy.

Phase

0.0 miles

Learn More »

DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma

Survival for patients with high risk aggressive B-cell lymphoma is still unsatisfied. Dose-intensified immunochemotherapy might improve the outcome. But for patients who could not achieve CR after the dose-intensified induction therapy, the prognosis is poor. The DLCL002 protocol is a total therapy which including induction therapy, rescue therapy and autologous …

Phase

0.0 miles

Learn More »

Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell Lung Cancer

This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that over express c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand the group(s) to further evaluate efficacy in the selected population(s) (Stage …

Phase

2.18 miles

Learn More »

Evaluate the Safety Tolerability and Antiviral Activity of GLS4 With Ritonavir in Patients With Chronic HBV Infection

About 125 subjects were planned to be included and assigned to the experimental group and the control group according to 4:1.At the same time, a liver biopsy group was set up in each part of the population to receive liver biopsy during the screening period and 48 weeks after completion …

Phase

2.18 miles

Learn More »

A Study of Lorlatinib in ALK Inhibitor Treated ALK Positive NSCLC in China

This is a Phase 2, China only, multi center, open label, dual cohort study, in ALK positive locally advanced or metastatic NSCLC patients will be enrolled to receive lorlatinib monotherapy. (in Cohort 1) Disease progression after crizotinib as the only ALK inhibitor. (in Cohort 2) Disease progression after one ALK …

Phase

2.18 miles

Learn More »